医薬品リファレンス

Ponesimod

Ponesimod is a medicine in the class central nervous system. It is used for multiple sclerosis.

薬効分類: Central Nervous System
効能・効果: multiple sclerosis

最終更新日 13 10月 2026

医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。

このページの臨床コンテンツは英語でのみ提供されています。

要点

薬効分類: Central Nervous System
ATCコード: L04AE04
一般的な剤形: 錠剤
一般的な規格: 20 mg, 2 mg, 10 mg
既知の相互作用: 127 (併用禁忌: 2 · 重大: 46 · 中等度: 71 · 軽度: 8)
商品名: 5
国・市場: 4

剤形、規格、商品名は国によって異なります。お手元の製品をご確認ください。

何に使われるか

Multiple sclerosis

作用のしくみ

Sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1

成人の通常用量（添付文書の要約）

Multiple Sclerosis (Initiation) Starter pack must be used for initiating treatment: 2 mg PO qDay initially; increase dose as per dose titration regimen (14-day titration)

添付文書の最初の用法・用量の行のみの要約です。用法・用量の全項目はアプリでご覧いただけます。

妊娠と授乳

妊娠: Unsafe EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving.
授乳: Unsafe No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.

報告されている副作用

Somnolence
Elevated hepatic transaminases
Hypertension
Urinary tract infection
Dyspnea
Dizziness

禁忌

Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has functioning pacemaker
In the past 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure (HF) requiring hospitalization, or Class III/IV HF

注意が必要な方

Consider possibility of severe exacerbation of disease after discontinuing therapy; monitor for severe increase in disability upon discontinuation and appropriately treat; after stopping therapy in the setting of PML, monitor for development of immune reconstitution inflammatory syndrome (PML-IRIS)
Elevated transaminases may occur; if symptoms (eg, unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, jaundice, dark urine) occur during therapy, check hepatic enzymes; if significant liver injury confirmed, discontinue therapy

妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。

主な相互作用 (127)

Fingolimod + Ponesimod Contraindicated
Ponesimod + Siponimod Contraindicated
Amiodarone + Ponesimod Major
Amisulpride + Ponesimod Major
Anagrelide + Ponesimod Major
Anti-thymocyte + Ponesimod Major
Asenapine + Ponesimod Major
Atenolol + Ponesimod Major
Atenolol-chlorthalidone + Ponesimod Major
Betaxolol + Ponesimod Major

All 127 interactions, with severity and what to do

Pro+会員向け

ページ全体を見る

アカウントを作成してPro+トライアルを始めると、Ponesimodの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。

Dosing by age, kidney and liver function, and further dose lines
Renal and hepatic dose adjustments
Paediatric dosing
How to give it
Pharmacokinetics
Patient counselling points
Food interactions

無料アカウントを作成ログイン

WebでPro+を14日間無料でお試し。カード登録不要。

同じ分類のほかの薬剤

よくある質問

What is Ponesimod used for?

Ponesimod is a medicine in the class central nervous system. It is used for Multiple sclerosis.

What side effects have been reported with Ponesimod?

Somnolence, Elevated hepatic transaminases, Hypertension, Urinary tract infection, Dyspnea, Dizziness.

Can Ponesimod be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving. Breastfeeding: Unsafe. No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.

What does Ponesimod interact with?

MediHelp lists 127 known interactions for Ponesimod. Contraindicated: 2 · Major: 46 · Moderate: 71 · Minor: 8. The most serious include Fingolimod, Siponimod, Amiodarone.

完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで

MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。

ダウンロード：App Store 入手：Google Play

A–Zで探す · 医薬品リファレンス